Status
Conditions
Treatments
About
This is an open label study of Ampligen in patients with chronic fatigue syndrome.
Full description
An Open-Label Study of Poly I: Poly C12U (Ampligen®) in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME). The FDA approved the study for cost recovery. Patients enrolled in the study are responsible for costs related to the therapy, e.g., drug cost, infusion cost, cost of supplies, diagnostic and other laboratory testing.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Diane Young; Ann Marie Coverly
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal